Literature DB >> 21452291

Tyr³²³-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity.

Mercedes López-Santalla1, María Salvador-Bernáldez, Isidoro González-Alvaro, Santos Castañeda, Ana M Ortiz, María Isabel García-García, Leonor Kremer, Fernando Roncal, Juan Mulero, Carlos Martínez-A, Jesús M Salvador.   

Abstract

OBJECTIVE: The p38 MAPK is important in the pathogenic immune response in rheumatoid arthritis (RA). The p38 molecule can be activated through phosphorylation on Thr¹⁸⁰-Tyr¹⁸² by upstream MAPK kinases and via an alternative pathway through phosphorylation on Tyr³²³. We undertook this study to quantify the phosphorylation of Tyr³²³ p38 and of Thr¹⁸⁰-Tyr¹⁸² p38 on T cells from healthy controls and patients with RA or ankylosing spondylitis (AS) to identify variables associated with p38 phosphorylation and disease activity.
METHODS: We measured p38 phosphorylation on Tyr³²³ and Thr¹⁸⁰-Tyr¹⁸² by flow cytometry and Western blotting on T cells from 30 control subjects, 33 AS patients, 30 patients with RA in remission, and 79 patients with active RA. We collected the clinical characteristics and analyzed correlations between clinical variables, the Disease Activity Score in 28 joints (DAS28), and p38 phosphorylation levels. Multivariate regression analysis was performed to identify variables associated with p38 phosphorylation on Tyr³²³ and Thr¹⁸⁰-Tyr¹⁸².
RESULTS: Phosphorylation of p38 on Tyr³²³ was higher in T cells from patients with active RA (P = 0.008 versus healthy controls) than in patients with RA in remission or in patients with AS. Tyr³²³ p38 phosphorylation was associated with disease activity determined by the DAS28 (P = 0.017). Enhanced p38 phosphorylation was linked to Lck-mediated activation of the Tyr³²³-dependent pathway in the absence of upstream MAPKK activation.
CONCLUSION: Our results indicate that phosphorylation status on Tyr³²³ p38 correlates with RA disease activity and suggest that the Tyr³²³-dependent pathway is an attractive target for down-regulation of p38 activity in RA patients.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21452291     DOI: 10.1002/art.30375

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  The Candida albicans toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways.

Authors:  Spyridoula-Angeliki Nikou; Chunsheng Zhou; James S Griffiths; Natalia K Kotowicz; Bianca M Coleman; Mary J Green; David L Moyes; Sarah L Gaffen; Julian R Naglik; Peter J Parker
Journal:  Sci Signal       Date:  2022-04-05       Impact factor: 8.192

2.  Characterization of the Phosphoproteome in SLE Patients.

Authors:  Xinzhou Zhang; Hualin Ma; Jianrong Huang; Yong Dai
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

Review 3.  Immunoregulatory molecules are master regulators of inflammation during the immune response.

Authors:  Hortensia de la Fuente; Danay Cibrián; Francisco Sánchez-Madrid
Journal:  FEBS Lett       Date:  2012-07-20       Impact factor: 4.124

Review 4.  Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

Authors:  George Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

5.  Discs Large Homolog 1 Splice Variants Regulate p38-Dependent and -Independent Effector Functions in CD8+ T Cells.

Authors:  Oscar Silva; Jillian Crocetti; Lisa A Humphries; Janis K Burkhardt; M Carrie Miceli
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

6.  The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis.

Authors:  Diletta Di Mitri; Manolo Sambucci; Maria Loiarro; Marco De Bardi; Elisabetta Volpe; Maria Teresa Cencioni; Claudio Gasperini; Diego Centonze; Claudio Sette; Arne N Akbar; Giovanna Borsellino; Luca Battistini
Journal:  Immunology       Date:  2015-07-06       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.